Merck & Co., Inc. (MRK) — closed signal from September 30, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 29, 2025.
Predicted vs. what happened
What happened
Reached its target in 1 day.
The thesis — published September 30, 2025
Merck looks like a steady, lower-drama stock that has dropped more than usual and could rebound. A late-September study showed its WINREVAIR drug cut disease worsening by 76 percent, boosting confidence in its research. A new AI partner may help Merck find medicines faster. Even if a common price signal is weak, real progress and a strong lineup could pull the stock back toward its recent average this quarter.
Primary drivers
- Late-September WINREVAIR study cut disease worsening by 76 percent
- AI-focused partner aims to speed up how Merck discovers new drugs
- Price looks washed out, offering a possible short-term bounce entry
- Stable earnings make the stock more resilient during tough markets
How it played out
MRK: target reached in 1 day
Lyra published MRK at 78.19 on 2025-09-30 with 12% expected growth and an 86.83 target. The thesis pointed to a late-September WINREVAIR study that cut disease worsening by 76 percent, a drug-discovery partnership tied to artificial intelligence, a washed-out price setup, and stable earnings.
Inside the window, MRK reached the 86.83 target after 1 day. The stock later rose to a 107.59 peak on 2025-12-29, with a 37.6% peak gain. It ended at 106.62. The thesis played out and then went well past the target.
What happened during the window
On 2025-10-30, Merck reported third-quarter sales of $17.28 billion and adjusted earnings per share of $2.58. The same report said WINREVAIR sales rose 141% year over year to $360 million.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.